Department of Neurology, Second Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215004, China
Location status: Recruiting
Location contact
Chun-Feng Liu, Ph.D, M.D.
CONTACT
Chun-Feng Liu, Ph.D,M.D.
PRINCIPAL_INVESTIGATOR
NCT Number: NCT06129942
The aim of this randomized controlled trial (RCT) is to clarify the effect of bright light therapy on motor symptoms and sleep disorders in patients with Parkinson's disease.
Interested in participating?
Request Info50 year–80 year
All sexes
Interventional
Not applicable
Suzhou, Jiangsu, 215004, China
Location status: Recruiting
Chun-Feng Liu, Ph.D, M.D.
CONTACT
Chun-Feng Liu, Ph.D,M.D.
PRINCIPAL_INVESTIGATOR
As the most important biologic rhythm timer, exogenous light supplement has certain benefits for the improvement of sleep quality and dementia. At present, it is gradually used in sleep and neuropsychiatric diseases. In an open study, 120 patients with PD received 4000 to 6000 lux of light, for 60 minutes before habitual bedtime. The patients were followed up for several months to 8 years, and it found the patients who persisted in the treatment improved their mood, anxiety and motor function. Clinical studies have confirmed the safety and effectiveness of light in improving insomnia and daytime sleepiness of PD patients. It was found that strong light can significantly improve the patients' motor and non-motor symptoms. However, these findings have not been reported in Chinese PD patients. The aim of this randomized controlled trial (RCT) is to clarify the effect of bright light therapy on motor symptoms and sleep disorders in patients with Parkinson's disease and explore the possible mechanism.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The light box uses a spectrally transparent prism diffuser, which can block ultraviolet rays, but will not affect the quality of the filtered light and will not turn yellow. The distance between the light box and the patient should not exceed 65cm.PD patients are selected for light intervention of different intensities. The experimental group is treated with 10,000 Lux intensity. The treatment time is 1 hour each day from 08:00-11:00 in the morning and 17:00-19:00 in the afternoon lasting for a month. The patient is asked to move under the light source, but should not fall asleep.
The light box uses a spectrally transparent prism diffuser, which can block ultraviolet rays, but will not affect the quality of the filtered light and will not turn yellow. The distance between the light box and the patient should not exceed 65cm.PD patients are selected for light intervention of different intensities. The control group is treated with 300 Lux intensity. The treatment time is 1 hour each day from 08:00-11:00 in the morning and 17:00-19:00 in the afternoon lasting for a month. The patient is asked to move under the light source, but should not fall asleep.
Time frame: visit1(baseline),visit2(4th week),visit3(8th week),visit4(12th week)
Total sleep time is the sum of sleep time in each period. This outcome reflects change of patients' sleep quality.
Time frame: visit1(baseline),visit2(4th week),visit3(8th week),visit4(12th week)
Sleep efficiency is the ratio of the total time spent asleep (total sleep time) in a night compared to the total amount of time spent in bed. This outcome reflects change of patients' sleep quality.
Time frame: visit1(baseline),visit2(4th week),visit3(8th week),visit4(12th week)
REM sleep without atonia (RWA) is the PSG finding of persistent muscle tone during REM sleep, resulting in paroxysmal phasic or tonic EMG activity. Together with dream-enacting behavior (DEB), RSWA is a necessary diagnostic criterion of REM sleep behavior disorder (RBD). This outcome reflects change of RBD severity.
Time frame: visit1(baseline),visit2(4th week),visit3(8th week),visit4(12th week)
Sleep latency is the amount of time it takes patients to go from being fully awake to sleeping. Patients' sleep latency and how quickly they reach rapid eye movement (REM) sleep can be indicators of the amount and quality of sleep they are getting.
Time frame: visit1(baseline),visit2(4th week),visit3(8th week),visit4(12th week)
Periodic limb movement during sleep (PLMS) is is described as a stereotypical involuntary movement during sleep. In particular, presenting more than 15 periodic limb movements per hour is related to daytime sleepiness due to low sleep quality. This outcome reflects change of patients' sleep quality.
Time frame: visit1(baseline),visit2(4th week),visit3(8th week),visit4(12th week)
Changes in the length and percentage of N1, N2, N3 and REM sleep,which reflect changes in sleep structure.
Time frame: visit1(baseline),visit2(4th week),visit3(8th week),visit4(12th week)
SWA and SWE are indicators of sleep depth and homeostasis in PSG.
Time frame: visit1(baseline),visit2(4th week),visit3(8th week),visit4(12th week)
MDS Unified Parkinson's Disease Rating Scale (MDS-UPDRS) is an effective tool to evaluate the severity of motor symptoms in patients with Parkinson's disease (PD).Each item is simply given a 5- point score: 0 (Absent) to 4 (Marked in amplitude and present most of the time).The higher the MDS-UPDRS score is, the worse the symptoms are.
Time frame: visit1(baseline),visit2(4th week),visit3(8th week),visit4(12th week)
In H-Y scale, PD is divided into 5 stages according to the range and extent of motor symptoms. The higher the H-Y scale is, the worse the symptoms are.
Time frame: visit1(baseline),visit2(4th week),visit3(8th week),visit4(12th week)
The Parkinson's Disease Sleep Scale-2(PDSS-2) assesses a wide spectrum of disease-specific sleep problems.
Time frame: visit1(baseline),visit2(4th week),visit3(8th week),visit4(12th week)
The Pittsburgh sleep quality index (PSQI) is widely used to measure sleep quality. The best cut-off score was 7. The higher the PSQI score is, the worse the sleep quality is.
Time frame: visit1(baseline),visit2(4th week),visit3(8th week),visit4(12th week)
REM sleep behavior disorder questionnaire-Hong Kong (RBDQ-HK) is widely used to assess the severity of RBD. The higher RBD-HK score is, the worse the symptoms are. In East China, the best cut-off value for RBDQ-HK was located at 17 with a sensitivity of 85% and specificity of 81% (AUC = 0.892) .
Time frame: visit1(baseline),visit2(4th week),visit3(8th week),visit4(12th week)
The Epworth sleepiness scale (ESS) measures daytime sleepiness. The best cut-off score was 10.The higher the ESS score is, the worse the excessive sleepiness symptoms are.
Time frame: visit1(baseline),visit2(4th week),visit3(8th week),visit4(12th week)
The Morningness-Eveningness Questionnaire (MEQ) is the most widely known questionnaire to assess circadian preference. Cut-off points were evaluated: a range of 14-52 for Evening types, 53-64 for neither types, and 65-86 for Morning types.
Time frame: visit1(baseline),visit2(4th week),visit3(8th week),visit4(12th week)
The Hamilton Anxiety Scale(HAMA) is a widely used interview scale to measure the severity of a patient's anxiety . The HAMA score can range from 0 to 56. The higher the HAMA score is, the worse the symptoms are. The best cut-off score was14.
Time frame: visit1(baseline),visit2(4th week),visit3(8th week),visit4(12th week)
The Hamilton Depression Scale-24(HAMD-24) is a test measuring the severity of depressive symptoms in individuals. The HAMA score can range from 0 to 56. The higher the HAMA score is, the worse the symptoms are.An optimal HAMD-24 cut-off score for distinguishing between patients with and without a depressive disorders was found to be 9/10,with a high area under the curve(AUC) (0.91) indicating excellent discrimination.
Time frame: visit1(baseline),visit2(4th week),visit3(8th week),visit4(12th week)
Montreal Cognitive Assessment (MoCA) is widely used to assess cognitive dysfunction. The MoCA score can range from 0 to 30.The best cut-off score was 26. The higher the MoCA score is, the better the cognitive function is.
Time frame: visit1(baseline),visit2(4th week),visit3(8th week),visit4(12th week)
Non-Motor Symptoms Questionnaire(NMSQ)contains 30 items and requires patients to answer "yes" and "no" according to their own situation in the last month. It is widely used in the assessment of PD patients' non motor symptoms.
Time frame: visit1(baseline),visit2(4th week),visit3(8th week),visit4(12th week)
The Parkinson's Disease Questionnaire (PDQ-39) is the most frequently used disease-specific health status measure.PDQ-39 total score equal or above 47 was the optimal cut-off associated with a high caregiver strain with a sensitivity of 83% and a specificity of 64% .
Time frame: visit1(baseline),visit2(4th week),visit3(8th week),visit4(12th week)
The Fatigue Severity Scale (FSS) is a scale used in the evaluation of fatigue that affects patients. A list of 9 statements is provided. The best cut-off score was 4.
Time frame: visit1(baseline),visit2(4th week),visit3(8th week),visit4(12th week)
Amplitudes of various frequency bands in each cortical region of EEG reflects change of cortical activity.
Time frame: visit1(baseline),visit2(4th week),visit3(8th week),visit4(12th week)
We collected saliva of participants in sections for 24 hours (6:00, 9:00, 12:00, 15:00, 18:00, 19:00, 20:00, 21:00, 22:00, 23:00, ten time points in total) and serum(8:00,20:00)to detect the level of melatonin. This outcome reflects change of biological rhythm.
Time frame: visit1(baseline),visit2(4th week),visit3(8th week),visit4(12th week)
We collected saliva of participants in sections for 24 hours (6:00, 9:00, 12:00, 15:00, 18:00, 19:00, 20:00, 21:00, 22:00, 23:00, ten time points in total) and serum(8:00,20:00)to detect the level of cortisol. This outcome reflects change of biological rhythm.
Time frame: visit1(baseline),visit2(4th week),visit3(8th week),visit4(12th week)
The functional connections between each brain region and brain network analysis of fMRI reflects change of brain network.
Contact information is provided by the study sponsor or research team.
Second Affiliated Hospital of Soochow University
Other
Light Therapy in Parkinson's Disease: a Prospective, Observational Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04291014
Basal Ganglia Diseases, Brain Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT06642454
Apathy, Basal Ganglia Diseases
Hefei, Anhui, China
View Trial DetailsNCT05599035
Basal Ganglia Diseases, Brain Diseases
Asyut, Egypt
View Trial DetailsNCT07323121
Basal Ganglia Diseases, Brain Diseases
Nanjing, Jiangsu, China
View Trial Details